Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer
Abstract Background The efficacy of bevacizumab in non-small cell lung cancer (NSCLC) patients is unsatisfactory, and the selection of suitable patients is still challenging. Given the epigenetic modifications can contribute to an aberrant regulation of angiogenesis and microenvironment, we investig...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2022-07-01
|
| Col·lecció: | BMC Cancer |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12885-022-09918-1 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|